Pre-Clinical Evaluation of CD38 Chimeric Antigen Receptor Engineered T Cells for the Treatment of Multiple Myeloma

Haematologica - Italy
doi 10.3324/haematol.2015.137620
Full Text
Abstract

Available in full text

Categories
Hematology
Date
Authors
Publisher

Ferrata Storti Foundation (Haematologica)

Related search

Chimeric Antigen Receptor T Cell Therapies for Multiple Myeloma

Journal of Hematology and Oncology
Cancer ResearchOncologyHematologyMolecular Biology
2019English

Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma

International Journal of Hematology
Hematology
2020English

Chimeric Antigen Receptor T Cells for the Treatment of Lymphoma

Annals of Lymphoma
2017English

768. Improved Chimeric Antigen Receptor-Engineered T Cells for the Treatment of Refractory and Relapsed Leukemia

Molecular Therapy
Molecular MedicineMolecular BiologyPharmacologyMedicineGeneticsDrug Discovery
2014English

Chimeric Antigen Receptor T-Cells

Cancer Journal
Cancer ResearchOncology
2015English

Chimeric Antigen Receptor T Cell Targeting B Cell Maturation Antigen Immunotherapy Is Promising for Multiple Myeloma

Annals of Hematology
MedicineHematology
2019English

Selinexor‐based Regimens for the Treatment of Myeloma Refractory to Chimeric Antigen Receptor T Cell Therapy

British Journal of Haematology
Hematology
2020English

247. Phase I Study of Second Generation Chimeric Antigen Receptor-Engineered T Cells Targeting IL13Rα2 for the Treatment of Glioblastoma

Molecular Therapy
Molecular MedicineMolecular BiologyPharmacologyMedicineGeneticsDrug Discovery
2016English

Retargeting CD19 Chimeric Antigen Receptor T Cells via Engineered CD19-Fusion Proteins

English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy